Abstract 882P
Background
While strong evidence indicates quitting smoking reduces the risk of developing head and neck cancer (HNC), it remains unclear whether patients who smoke could still benefit from quitting after HNC diagnosis. We investigated the impact of postdiagnosis smoking cessation on the survival of patients with HNC who smoked at diagnosis.
Methods
This prospective study included 1,298 participants who were diagnosed with HNC in the United Kingdom (Head and Neck 5000 study, recruitment: 2011-2014), and 4 countries in Latin America (Brazil, Argentina, Uruguay, and Colombia - INTERCHANGE study, recruitment: 2011-2017) who actively smoked at diagnosis. Participants have been actively followed since their diagnosis to collect regular information on their smoking behavior and disease status. Overall survival was evaluated using extended Kaplan-Meier curves and time-dependent Cox proportional hazards regression models.
Results
During the follow-up, 442 participants (34%) reported quitting smoking, and 571 deaths were recorded. Median survival time was 17 months higher when patients quit vs. continued smoking (median survival time = 6.6 vs. 5.2 years, p<0.001). At 5-years, the survival rate was significantly higher when patients quit vs. continued smoking (61.0% vs. 50.6%, p<0.001). After accounting for the quitting time and adjusting for potential confounders, quitting smoking was associated with 33% lower risk of death compared to continued smoking (HR=0.67, 95%CI=0.56-0.81). Stratified analyses revealed consistent survival benefits associated with quitting smoking among all patient subgroups, including those who reported mild-moderate vs. heavy smoking, and patients who were diagnosed with earlier vs. later-stage tumors. The benefits of quitting smoking were also evident across various HNC subtypes.
Conclusions
Quitting smoking after HNC diagnosis may significantly reduce the risk of death and improve survival among patients who smoke. These findings underscore the importance of post-diagnosis smoking cessation interventions as part of comprehensive cancer care for HNC patients.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
761P - Anti-angiogenic therapy in first-line treatment of low-grade serous ovarian cancer: Exploratory meta-analysis of the prospective AGO-OVAR 11/12/16 studies
Presenter: Bastian Czogalla
Session: Poster session 02
762P - First results from phase II dose expansion cohort of transcon IL-2 β/γ in combination with standard of care chemotherapy for platinum resistant ovarian cancer (PROC) in the IL Believe trial
Presenter: Oladapo Yeku
Session: Poster session 02
763P - Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance
Presenter: Pamela Soberanis Pina
Session: Poster session 02
765P - HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers
Presenter: Dahye Lee
Session: Poster session 02
766P - A phase II trial of fuzuloparib in combination with apatinib vs. fuzuloparib alone for recurrent ovarian cancer (OC)
Presenter: Jianqing Zhu
Session: Poster session 02
767P - Ovarian cancer risk factors in relation to family history
Presenter: Guoqiao Zheng
Session: Poster session 02
768P - Reclassification and variant distribution in the GINECO GREAT study of ovarian cancer patients: Insights into HRD status
Presenter: Etienne Rouleau
Session: Poster session 02
770P - Neoadjuvant pembrolizumab in stage IV ovarian cancer: The phase II Neo-Pembro trial
Presenter: Lot Aronson
Session: Poster session 02
771P - Claudin-6 expression in primary and recurrent epithelial ovarian cancer: A potential therapeutic target for high-grade serous ovarian cancer
Presenter: Daisuke Shintani
Session: Poster session 02